Vascular endothelial growth factor (VEGF) is a potent regulator of vasculogenesis
Vascular endothelial growth factor (VEGF) is a potent endothelial cell-specific regulator of vasculogenesis and angiogenesis. 1, 2 Increased VEGF expression, resulting in VEGF-induced angiogenesis is associated with tumour growth and metastasis, 3 since solid tumours cannot grow larger than 2-3 mm 3 and cannot metastasise without the formation of new blood vessels. In such tumours, VEGF, whose expression is regulated by a number of hormones, growth factors and cytokines, such as interleukin (IL)-10, can be produced by tumour cells and tumour infiltrating T cells and macrophages. 4, 5 In cutaneous malignant melanoma (CMM), a number of studies have reported increased immunoreactivity for VEGF in neoplastic as opposed to benign melanocytic lesions, 6 with elevated expression in metastatic melanoma. 7 Tumour vascularity in metastatic melanoma has also been shown to be of prognostic value. 7 In addition, in a murine model, it has been claimed that constitutive, genetically determined levels of VEGF expression may be more important than Recently, a number of single nucleotide polymorphisms (SNPs) have been described in the VEGF gene (chrom 6p12), which have been reported to be associated with differential VEGF expression in vitro. [9] [10] [11] [12] Two of these SNPs (positions −2578 and −1154) are located in the VEGF promoter region, 9, 12 one SNP (+405) in exon 1 of the VEGF gene 10 and a further SNP (+936) located in exon 8, corresponding to the 3′ untranslated (UTR) region of the gene. 11 Other SNPs have also been described, although a relationship with VEGF expression has not been demonstrated. 10 Based on the above, in this study we have determined whether the above VEGF-associated SNPs are associated with susceptibility to or prognosis in CMM. To achieve this, genotyping and haplotype analysis for VEGF −2578, −1154, +405 and +936 SNPs in a series of 152 CMM patients was performed, utilizing DNA extracted from diagnostic histopathological formalin-fixed, wax-embedded tissues. 13 The following clinical and pathological markers were examined as indicators of prognosis: initial growth phase (horizontal vs vertical), mitotic count within vertical growth phase tumours, Breslow depth of invasive CMM and stage of disease.
14 Among these factors, Breslow thickness at presentation is the most important single prognostic indicator in CMM. [15] [16] [17] Patient survival was also determined according to VEGF genotype. In addition, VEGF genotypes and assigned haplotypes were compared between the CMM patients and a series of 266 unrelated controls (bone marrow and cadaveric solid organ donors), to determine whether VEGF genotype influences susceptibility to CMM. Linkage disequilibrium and haplotype analyses were performed according to previously published methods. 18, 19 
Results and discussion
All control samples were genotyped for VEGF −2578, and between 238 and 263 samples were genotyped for the remaining three SNPs, depending on DNA availability. Genotype and allele frequencies were in close agreement with those previously published for healthy Caucasian individuals. [9] [10] [11] Similarly, all CMM samples were genotyped for VEGF −1154 and between 137 and 144 samples were genotyped for the remaining three SNPs, subject to DNA availability. There were no significant differences in VEGF genotype frequencies between CMM patients and controls at P = 0.05 (Table 1 ). In addition, no significant associations with tumour growth phase were demonstrated. However, results indicate that the VEGF −1154 AA genotype was decreased in frequency among CMM patients with Stage II-IV disease, compared with Stage I disease, at a marginal level of significance (3/55 (5.5%) vs 14/84 (16.7%); Fisher's exact P = 0.03; OR = 0.3 (0.1-1.1)) (VEGF −1154 AA has been shown to be associated with significantly lower VEGF expression than GA or GG genotypes 12 ). VEGF genotypes were also compared with the frequency of mitotic figures in vertical growth phase tumours. No genotypes were significantly associated with mitotic count. Finally, VEGF genotypes were compared among patients with vertical growth phase tumours stratified according to Breslow thickness of their primary tumours (Table 2) . At the clinically significant cut-off point of 0.75 mm, the VEGF −1154 AA genotype was significantly decreased in frequency among tumours with a thickness of у0.75 mm (4/80 (5.0%) vs 7/22 (31.8%); Fisher's exact P = 0.002; OR = 0.1 (0.03-0.4)). When stratifying tumours according to Breslow thickness of greater or less than 1.5 mm, the VEGF −1154 GG genotype was significantly increased in frequency among patients with thicker tumours (32/48 (66.7%) vs 24/54 (44.4%); P = 0.02; OR = 2.5 (1.1-6.0)). Insufficient CMM patients had tumours with a Breslow thickness exceeding 3.5 mm for a viable analysis at this cut-off point. In addition, mean vertical growth phase tumour Breslow thickness was significantly greater among CMM patients with VEGF −1154 GG vs AA genotypes (3.1 ± 3.9 mm vs 0.8 ± 0.5 mm; Mann-Whitney U test, P = 0.002). Mean tumour thickness in CMM patients of VEGF −1154 GA genotype was of an intermediate value (2.1 ± 2.2 mm). Since VEGF −1154 GG has been shown to be associated with high VEGF expression compared with VEGF −1154 AA, 12 these results suggest that genotypes associated with increased VEGF expression are also associated with increased tumour Breslow thickness.
Only individuals typed for all four SNPs were included in the haplotype analysis (114 CMM patients and 224 controls). In this combined series, haplotype analysis revealed that the VEGF −2578, −1154 and +405 SNPs are in tight linkage disequilibrium (pairwise linkage disequilibrium coefficient = 0.488-0.965), while the VEGF +936 In Tables 1 and 2 P values and odds ratios are given where P р 0.05. P values for non-significant trends (P = 0.05-0.10) are also given. All other P values were non-significant. Genotype distributions were compared by 2 × 2 tables using 2 analysis or Fisher's exact test if one or more variables in 2 × 2 tables were Ͻ5.
PCR genotyping reactions (10 l) comprised 1× AS reaction buffer (ABgene, Epsom, UK), 200 M each dNTP, 12% (w/v) sucrose, 200 M cresol red, 1 M each specific/common primer (5′TAGGCC AGACCCTGGCAC3′ or 5′TAGGCCAGACCCTGGCAA3′ with 5′T GCCCCAGGGAACAAAGT3′ (−2578); 5′GCCCGAGCCGCGTGTG GAG3′ or 5′GCCCGAGCCGCGTGTGGAA3′ with 5′CCCCGCTAC CAGCCGACTT3′ (−1154); 5′CGTGCGAGCAGCGAAAGG3′ or 5′C GTGCGAGCAGCGAAAGC3′ with 5′TGTCCGTCAGCGCGACT G3′ (+405); 5′GGTCGGGTGACCCAGCAC3′ or 5′GGTCGGGTGAC CCAGCAT3′ with 5′GGGTGGGTGTGTCTACAGGA3′ (+936)), 0.2 M each internal control primer 22 (5′TGCCAAGTGGAGCACC CAA3′ and 5′GCATCTTGCTCTGTGCAGAT3′), 0.25 units Thermoprime PLUS DNA polymerase (ABgene) and 25-100 ng DNA. MgCl 2 concentrations were optimised for each SNP (2.0 mM for +405 and +936; 2.75 mM for −2578 and −1154). PCR conditions comprised 1 min at 96°, followed by 10 cycles of 96°for 15 s, T a o for each SNP (61°C for −1154; 65°C for +405 and +936; 65.5°C for −2578) for 50 s, 72°C for 40 s; then 20 cycles of 96°C for 10 s, 60°C for 50 s, 72°C for 40 s. (9600 Thermal Cycler (ABI, Foster City, CA, USA) or an MWG Primus 96
Plus Thermal Cycler (MWG Biotech UK Ltd, Milton Keynes, UK).) PCR products were loaded directly onto 2% agarose gels (containing 0.5 mg/ml ethidium bromide), electrophoresed and visualised by photography under UV transillumination.
SNP is only weakly associated with the other SNPs ( = 0.004-0.130). Given this, combined with the rarity of the VEGF +936 TT genotype (Table 1) , further haplotype analysis was restricted to the −2578, −1154 and +405 SNPs. From Table 3 it can be seen that of a possible eight haplotypes, one haplotype (VEGF −2578, −1154, +405 AGC) was not represented among CMM cases or controls, while a further three haplotypes (AAC, CAG and CAC) had a frequency of less than 0.1 in both patients and controls. No significant differences in haplotype frequencies between CMM patients and controls were detected.
These three SNP haplotypes were also compared within the patient series stratified according to clinical and histopathological prognostic indictors, by logistic regression and Breslow thickness by stepwise regression. From this analysis stage of disease was shown to be associated with the rare VEGF −2578, −1154, +405 CAC haplotype ( 2 = 4.659, 1 df, P = 0.03), with this haplotype associated with less advanced disease.
Finally, analysis of patient survival was performed in 108 subjects in which the primary tumour was fully excised by surgery. This revealed a non-significant trend towards improved survival among individuals of VEGF −1154 AA genotype compared with VEGF −1154 GA and GG genotypes (Log rank P = 0.2915) (Figure 1) . This is the first study to investigate whether SNPs reported to be associated with differential VEGF expression influence cancer susceptibility and tumour development, with CMM as exemplar. This is also the first study to investigate linkage disequilibrium and probable haplotypes for the four SNPs in question. Results obtained show evidence for strong linkage disequilibrium between the VEGF −2578, −1154 and +405 SNPs, but not between these SNPs and SNP +936. The reason for this lack of strong linkage disequilibrium between SNP +405 (exon 1) and SNP +936 (exon 8) is not clear. Findings also suggest that it is unlikely that any of the four VEGF SNPs or associated haplotypes investigated play a major role in susceptibility to CMM, Genes and Immunity although this cannot be entirely discounted by the present small study.
The most significant finding in the present study is that VEGF −1154 genotype appears to be associated with CMM tumour Breslow thickness, with the VEGF −1154 GG 'high expression' genotype found at a significantly higher frequency in CMM patients with a vertical growth phase tumour thickness equal to or greater than 1.5 mm compared with patients with thinner tumours. In addition, the VEGF −1154 AA 'low expression' genotype was found at a significantly higher frequency in CMM patients with vertical growth phase tumours of less than 0.75 mm compared with patients with thicker tumours. These findings are supported by further data analysis demonstrating that mean Breslow tumour thickness is significantly greater among CMM patients of VEGF −1154 GG 'high expression' genotype compared with patients of VEGF −1154 AA 'low expression' genotype. Of the remaining prognostic indicators examined, the VEGF −1154 AA 'low expression' genotype was found at a significantly increased frequency among CMM patients with Stage I as opposed to Stage II-IV disease. The find-ing is supported by haplotype analysis showing that the VEGF −2578, −1154, +405 CAC haplotype was associated with less advanced stage of disease. All of the above associations were significant before correction of P values for the number of genotypes compared (three genotypes for each of four SNPs). The VEGF −1154 AA association with thinner primary tumours remains significant after correction for the number of genotypes. In addition, there was a non-significant trend towards improved survival among patients of VEGF −1154 AA 'low expression' genotype, consistent with a direct influence of polymorphisms affecting VEGF expression on tumour growth.
Taken together, these results suggest that the VEGF −1154 SNP -or polymorphisms in linkage disequilibrium with this SNP -may influence tumour invasion in CMM, possibly via increased expression of VEGF, acting to promote tumour angiogenesis. We have previously reported that IL-10 promoter SNPs are associated with susceptibility to CMM and with tumour growth phase, Stage of disease and Breslow thickness in this patient series and have hypothesised that these associations may be due to IL-10 downregulation of a number of angiogenic factors, including VEGF. 13 Other explanations of IL-10 action, including downregulation of HLA class I expression and increased NK cell lysis remain plausible. 20, 21 An investigation of combined VEGF and IL-10 genotypes may therefore be informative, which could be addressed by a larger study than the present.
Results from this preliminary study therefore suggest that VEGF gene polymorphisms (which may be associated with differential VEGF expression) may influence tumour development in CMM. This preliminary finding requires confirmation in an independent study of a large CMM patient series, along with a definitive investigation of VEGF genotype influences on patient survival in this malignancy.
